| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ViGenCell Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,400.00 |
| 52 Week High | ₩7,900.00 |
| 52 Week Low | ₩4,375.00 |
| Beta | 1.2 |
| 1 Month Change | -10.39% |
| 3 Month Change | -11.56% |
| 1 Year Change | -36.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.21% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| A308080 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.6% | 0.1% | 1.5% |
| 1Y | -37.0% | 9.5% | 9.6% |
Return vs Industry: A308080 underperformed the KR Biotechs industry which returned 9.5% over the past year.
Return vs Market: A308080 underperformed the KR Market which returned 9.6% over the past year.
Price Volatility
| A308080 volatility | |
|---|---|
| A308080 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A308080 has not had significant price volatility in the past 3 months.
Volatility Over Time: A308080's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 74 | Kim Tai Gyu | www.vigencell.com |
ViGenCell Inc. specializes in immune cell therapy. It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use. The company was founded in 1995 and is based in Seoul, South Korea.
ViGenCell Inc. Fundamentals Summary
| A308080 fundamental statistics | |
|---|---|
| Market cap | ₩84.33b |
| Earnings (TTM) | -₩17.88b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs A308080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A308080 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩839.00k |
| Gross Profit | -₩839.00k |
| Other Expenses | ₩17.87b |
| Earnings | -₩17.88b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -932.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 10.4% |
How did A308080 perform over the long term?
See historical performance and comparison